Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Inclusion Criteria (condensed): * Multiple myeloma that is double-refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) after at least 2 prior lines of therapy OR have failed at least 3 prior lines of therapy * Measurable disease activity as indicated by serum or urine M-protein, serum free light chain, biopsy-proven plasmacytoma, \>5% bone marrow plasma cells. * Adequate vital organ function as indicated by ANC (\>1000/uL), platelet count (\>50,000/uL), hemoglobin (\>8 g/dL), serum ALT and AST (each \<3.0 x upper limit of normal), total bilirubin (\<2 mg/dL), creatinine clearance (\>30 mL/min), and cardiac ejection fraction (\>45%) Exclusion Criteria (condensed): NOTE: Prior anti-BCMA or CAR-T therapy is NOT exclusionary * Active plasma cell leukemia * Pregnant or lactating * Active, uncontrolled infection * Active and severe auto-immune disease * Active arrhythmia, or obstructive or restrictive pulmonary disease * Central nervous system disease